News | March 15, 2012

Devicor Enters Mammotome Distribution Agreement With Carbon Medical

March 15, 2012 — Devicor Medical Products Inc. announced that it signed a distribution agreement with Carbon Medical Technologies Inc. Under the agreement Devicor, parent company of Mammotome, will have exclusive rights to market a new beta-glucan tissue marker developed by Carbon Medical Technologies. Financial terms of the agreement were not disclosed.

The new marker will be used in breast biopsies to mark soft tissue at the diagnostic site. The unique design and proprietary material of the product allows for enhanced visibility in all imaging modalities.

"Doctors have told us that consistent and long-lasting visibility under ultrasound and other imaging modalities is important for the treatment of their patients. We believe this product provides that solution," says Tom Daulton, CEO of Devicor and Mammotome.

"We are pleased to partner with Devicor and believe that our work has resulted in a clinically important marker product," says Dean Klein, president and CEO of Carbon Medical Technologies.

Mammotome, the worldwide leader of biopsy site markers and vacuum-assisted biopsy devices, sells products in nearly 50 countries around the world. In addition to this new device, the Mammotome family of marker products, which is used in the diagnosis of breast disease, includes MammoMARK, CorMARK and MicroMARK II.

"Devicor is making tremendous progress toward our goal of building a global medical device business. Our agreement with Carbon Medical Technologies is another example of how our company is investing in innovative products that help clinicians more effectively diagnose and treat patients," says Daulton.

For more information:

Related Content

Comparison of Screening Recommendations Supports Annual Mammography
News | Mammography | August 22, 2017
When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue...
Sponsored Content | Videos | Breast Imaging | July 28, 2017
Nancy Cappello, Ph.D., executive director and founder of Are You Dense Inc. and Are You Dense Advocacy, explains how
Volpara Solutions to Showcase Volpara Enterprise DDP Software at AHRA 2017
News | Mammography | July 11, 2017
Volpara Solutions Inc. will showcase its new Volpara Enterprise DDP software at the Association for Medical Imaging...
Fujifilm Showcases Digital Radiography, Mammography Innovations at AHRA 2017
News | Digital Radiography (DR) | July 06, 2017
Fujifilm Medical Systems U.S.A. Inc. will present its comprehensive portfolio of digital radiography (DR) and...
Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50
News | Mammography | June 30, 2017
June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the
GE Healthcare Announces First U.S. Installation of Senographe Pristina Mammography System
News | Mammography | June 29, 2017
GE Healthcare has collaborated with Boca Raton Regional Hospital (Boca Raton, Fla.) to bring a more comfortable...
New Study Highlights Breakthrough Therapy to Reduce Mammographic Breast Density
News | Breast Density | June 28, 2017
Stephen N. Birrell, M.D., Ph.D., presented breakthrough findings into the reduction of mammographic breast density at...
Therapixel Wins the Digital Mammography Challenge
News | Mammography | June 23, 2017
June 23, 2017 — French radiology technology company Therapixel was recently named the winner of the Digital Mammograp
MRI Plus Mammography Improves Detection of New Breast Cancer After Surgery
News | Breast Imaging | June 22, 2017
A new article published by JAMA Oncology compares outcomes for combined mammography and magnetic resonance imaging (MRI...

Photo courtesy of Barco

News | Mammography | June 08, 2017
An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are...
Overlay Init